The company is highlighting HTD1801’s comprehensive cardiometabolic profile and its renal therapeutic potential through multiple scientific presentations at CVCT 2025.
ROCKVILLE, MD and SHENZHEN, CHINA – [Dec 9, 2025] – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company developing multifunctional, multi-targeted therapies for chronic metabolic diseases, today announced that it presents a series of scientific disclosures at the 22nd Global CardioVascular Clinical Trialists Forum (CVCT) in Washington, D.C.
HighTide Therapeutics presents clinical and preclinical data at the CVCT forum showing that HTD1801 improved kidney function and markers of renal injury with early chronic kidney disease (CKD). As a therapy designed to address the interconnected spectrum of cardiovascular–kidney–metabolic (CKM) disease, HTD1801 targets the shared metabolic and inflammatory pathways driving disease progression. Findings from the Phase III SYMPHONY program in patients with Type 2 Diabetes Mellitus (T2DM) demonstrate meaningful improvements in eGFR trajectory, while preclinical models showed reduced albuminuria, renal inflammation, and renal fibrosis. Together, the results support HTD1801’s potential as a novel, disease-modifying therapy targeting both metabolic dysfunction and inflammation.
HTD1801’s comprehensive CKM profile, renal evidence, and emerging potential in CKD are showcased across a series of scientific programs at the CVCT forum.
- Late-Breaking Oral Presentation
Title: Evidence of Kidney Protection with HTD1801 (an Anti-Inflammatory Metabolic Modulator (AIMM)) – A Potential Comprehensive Approach to Early Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Date/Time: Tuesday; December 9, 2025; 08:30 -10:30
Speaker: Dr. Filip Surmont
Presenting Author: Filip Surmont, Leili Gao; Kui Liu, Leigh MacConell, Meng Yu, Liping Liu, Linong Ji on behalf of the SYMPHONY Investigators
- Poster Presentation
Title: HTD1801, a Dual AMPK and NLRP3 First-in-Class Anti-Inflammatory Metabolic Modulator (AIMM), Improves eGFR in Phase III Type 2 Diabetes Trials Supporting Advancement to Phase IIb Study in CKD
Date/Time: Set-up: From 10:30 am on Monday, December 8th. The poster will be displayed throughout the three days of the conference.
Presenting Author: Filip Surmont, Leili Gao; Kui Liu, Leigh MacConell, Meng Yu, Liping Liu, Linong Ji on behalf of the SYMPHONY Investigators
- DCRI Session Opening Oral Presentation
Title: Beyond Glucose: Serendipitous Insights Into a Dual-Pathway Approach for CKM and HF Prevention.
Date/Time: Tuesday; December 9, 2025; 16:30 -18:30
Speaker: Dr. Filip Surmont
- DCRI Session Expert Panel Discussion
Topic: DCRI joint session – CARDIOVASCULAR PREVENTION TRIALS HEART FAILURE AS A USE CASE
Date/Time: Tuesday; December 9, 2025; 16:30 -18:30;
“We are extremely encouraged by the growing body of evidence supporting HTD1801’s potential to address the interconnected drivers of cardiovascular–kidney–metabolic disease,” said Dr. Liping Liu, Ph.D., Founder, Chairperson, and CEO of HighTide Therapeutics. “The renal improvements observed across our clinical and preclinical programs reinforce HTD1801’s promise as a differentiated, disease-modifying therapy. We look forward to sharing these data at CVCT and advancing the development of HTD1801 to bring meaningful benefits to patients living with chronic metabolic and kidney disorders”.
About HTD1801
HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is a biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for chronic metabolic diseases, with a strategic emphasis to address the residual risks of cardiovascular-kidney-metabolic (CKM) syndrome. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across chronic metabolic diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
For more information, please visit www.hightidetx.com.
Contact: pr@hightidetx.com